The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy

被引:13
|
作者
Xiao, Li-Xin [1 ]
Chen, Yi-Ru [2 ]
Huang, Ping [3 ]
Mei, Yong-Yu [1 ]
Pan, Calvin Q. [4 ,5 ]
Lin, Chao-Shuang [1 ]
机构
[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[3] Peoples Hosp Lianjiang, Dept Infect Dis, Lianjiang, Guangdong, Peoples R China
[4] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Dept Med, Beijing, Peoples R China
[5] NYU, Dept Med, Div Gastroenterol & Hepatol, Langone Hlth,Sch Med, 132-21 41 Ave, New York, NY 11355 USA
关键词
antiviral therapy; drug withdrawal; hepatitis B virus; mother-to-child transmission; HEPATITIS-B-VIRUS; REDUCES PERINATAL TRANSMISSION; TENOFOVIR DISOPROXIL FUMARATE; SURFACE-ANTIGEN; INFECTION; EFFICACY; TELBIVUDINE; FLARES; WOMEN; PREDICTORS;
D O I
10.1002/jmv.26011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of prenatal antiviral therapy (AVT) for preventing the vertical transmission of hepatitis B virus (HBV) is well demonstrated. However, data are limited regarding the safety of postpartum cessation of AVT, which may induce alanine aminotransferase (ALT) elevation. We aimed to investigate the necessity of prolonging maternal AVT after delivery. Chronic hepatitis B mothers at the immune-tolerant phase with HBV DNA levels >6 log(10) IU/mL were prospectively enrolled and received AVT during the third trimester until delivery. Patients were offered to discontinue AVT either at delivery or postpartum week (PPW) 6. In addition, mothers who deferred AVT during pregnancy served as the control group. All mothers were followed until PPW 52 for clinical and virological parameters of hepatitis flares. Among 118 mothers recruited, 91 received AVT with 53 (group A) and 24 (group B) discontinue their treatment at delivery and PPW 6, respectively. Twenty-seven mothers who deferred AVT during pregnancy were followed as the control (group C). A total of 104 of 118 mothers who completed the study, 50% (52/104) had postpartum-elevated ALT levels, which were mild and moderate except 6 of 104 (5.77%) of patients had levels >= 5 times the upper limit of normal; 70% (36/52) of the ALT flares occurred within 12 weeks after delivery. In subgroup analyses, the frequency of ALT elevation was similar among the groups A vs B vs C (50.9% [27/53] vs 58.3% [14/24] vs 40.7% [11/27], respectively;P = .447), as well as the mean peak ALT level (108.4/74.1/126.7 U/L in groups A/B/C, respectively;P = .291). Although postpartum ALT flares were common for mothers with or without AVT during pregnancy, most cases of ALT elevation were mild to moderate. Our study observed that extending AVT to PPW 6 did not affect maternal outcomes and ATV should be discontinued at birth. Close monitoring is warranted as severe flares rarely occurred.
引用
收藏
页码:3381 / 3389
页数:9
相关论文
共 50 条
  • [41] Prevention of mother-to-child transmission of HIV - An overview
    Merchant, RH
    Lala, MM
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2005, 121 (04) : 489 - 501
  • [42] ART in Prevention of Mother-to-Child Transmission of HIV
    Gupta, Abhilasha
    Verma, Aruna
    Kashyap, Monika
    Gautam, Priti
    JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA, 2020, 70 (01): : 18 - 22
  • [43] Raltegravir for prevention of mother-to-child transmission of HIV
    Trahan, Marie-Julie
    Lamarre, Valerie
    Metras, Marie-Elaine
    Lapointe, Normand
    Kakkar, Fatima
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [44] Pharmacogenomics and the prevention of mother-to-child transmission of HIV
    Cressey, Tim R.
    Lallemant, Marc
    PHARMACOGENOMICS, 2010, 11 (01) : 1 - 4
  • [45] Recent advances in the prevention of mother-to-child transmission
    McIntyre, James
    Lallemant, Marc
    CURRENT OPINION IN HIV AND AIDS, 2008, 3 (02) : 136 - 138
  • [46] eHealth and Prevention of Mother-to-Child Transmission of HIV
    Grace John-Stewart
    Current HIV/AIDS Reports, 2018, 15 : 350 - 357
  • [47] Hope for prevention of mother-to-child transmission of HIV
    Clark, S
    LANCET, 2000, 356 (9226): : 316 - 316
  • [48] Prevention of mother-to-child transmission of toxoplasmosis: Perspectives
    Mandelbrot, L.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2012, 40 (10): : 591 - 598
  • [49] Advances in prevention of mother-to-child HIV transmission
    Chokechai Rongkavilit
    Basim I. Asmar
    The Indian Journal of Pediatrics, 2004, 71 (1) : 69 - 79
  • [50] eHealth and Prevention of Mother-to-Child Transmission of HIV
    John-Stewart, Grace
    CURRENT HIV/AIDS REPORTS, 2018, 15 (04) : 350 - 357